Thromb Haemost 1984; 51(02): 204-206
DOI: 10.1055/s-0038-1661059
Original Article
Schattauer GmbH Stuttgart

Acylated Streptokinase – Plasminogen Complex in Patients with Acute Myocardial Infarction

Isobel D Walker
1   The Department of Haematology, Royal Infirmary, Glasgow, U. K
,
J F Davidson
1   The Department of Haematology, Royal Infirmary, Glasgow, U. K
,
A P Rae
2   The University Department of Cardiology, Royal Infirmary, Glasgow, U. K
,
I Hutton
2   The University Department of Cardiology, Royal Infirmary, Glasgow, U. K
,
T D V Lawrie
2   The University Department of Cardiology, Royal Infirmary, Glasgow, U. K
› Author Affiliations
Further Information

Publication History

Received 05 September 1983

Accepted 20 January 1984

Publication Date:
19 July 2018 (online)

Preview

Summary

BRL 26921 is the p-anisoyl derivative of the primary streptokinase-human plasminogen complex in which the acyl group is specifically located at the catalytic centre of the enzyme. Doses of BRL 26921 ranging from 5 mg to 25 mg were given intravenously or into a coronary artery to 12 patients with acute myocardial infarction. The complex was well tolerated and produced no serious bleeding. Coronary artery reperfusion was demonstrated angiographically in three patients.

In most patients, fibrinogen, plasminogen, α2 antiplasmin and a2 macroglobulin levels fell and the level of fibrinogen degradation products increased acutely post treatment indicating systemic fibrinolytic activation. The degree of this activation was variable but was profound in some. It appeared to be dose related and modified by the presence of streptokinase antibodies. BRL 26921 appears less “selectively” thrombolytic in patients than had been expected from animal models.